Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST CARE Trial
2024-515333-14-03Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aspirin and ketorolac in cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Primary: clinical efficacy of experimental treatment and Primary: safety of experimental treatment. Planned start Dec 2025; status: authorised.
02
Drugs
aspirinketorolac
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-515333-14-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515333-14-03.